|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| feathers | CD66b Non | | |  | CD66b IM | | |  | CD66bTC | | |
| Low N(%) | High N(%) | *P* value |  | Low N(%) | High N(%) | *P* value |  | Low N(%) | High  (%) | *P* value |
| Age |  |  | 0.144 |  |  |  | 0.516 |  |  |  | 0.358 |
| <70 | 133 | 125 |  |  | 127 | 131 |  |  | 132 | 126 |  |
| ≥70 | 30 | 39 |  |  | 37 | 32 |  |  | 31 | 38 |  |
| Gender |  |  | 0.437 |  |  |  | 0.129 |  |  |  | 0.831 |
| Male | 115 | 122 |  |  | 125 | 112 |  |  | 119 | 118 |  |
| Female | 48 | 42 |  |  | 39 | 51 |  |  | 44 | 46 |  |
| ASA status |  |  | 0.900 |  |  |  | 0.862 |  |  |  | 0.185 |
| <3 | 137 | 137 |  |  | 138 | 136 |  |  | 141 | 133 |  |
| ≥3 | 26 | 27 |  |  | 26 | 27 |  |  | 22 | 31 |  |
| Tumor site |  |  | 0.473 |  |  |  | 0.454 |  |  |  | 0.757 |
| Upper | 18 | 24 |  |  | 23 | 19 |  |  | 19 | 23 |  |
| Middle | 58 | 50 |  |  | 49 | 59 |  |  | 53 | 55 |  |
| lower | 87 | 90 |  |  | 92 | 85 |  |  | 91 | 86 |  |
| Tumor size |  |  | 0.864 |  |  |  | 0.993 |  |  |  | 0.348 |
| <5 | 73 | 75 |  |  | 75 | 76 |  |  | 78 | 70 |  |
| ≥5 | 90 | 89 |  |  | 89 | 90 |  |  | 85 | 94 |  |
| Pathological TNM stage |  |  | 0.130 |  |  |  | 0.257 |  |  |  | 0.016 |
| I | 27 | 23 |  |  | 27 | 23 |  |  | 28 | 22 |  |
| II | 30 | 48 |  |  | 44 | 34 |  |  | 48 | 30 |  |
| III | 82 | 75 |  |  | 77 | 80 |  |  | 73 | 84 |  |
| IV | 24 | 18 |  |  | 16 | 26 |  |  | 14 | 28 |  |
| Lauren classification |  |  | 0.202 |  |  |  | 0.654 |  |  |  | 0.353 |
| Intestinal | 83 | 98 |  |  | 87 | 94 |  |  | 87 | 94 |  |
| Diffuse | 30 | 29 |  |  | 30 | 29 |  |  | 27 | 32 |  |
| Mixed | 50 | 37 |  |  | 47 | 40 |  |  | 49 | 38 |  |
| Histological grade |  |  | 0.271 |  |  |  | 0.236 |  |  |  | 0.520 |
| G1/ G2 | 56 | 66 |  |  | 56 | 66 |  |  | 58 | 64 |  |
| G3/Signet ring cell/ Mucinous | 107 | 98 |  |  | 108 | 97 |  |  | 105 | 100 |  |
| Lymphovascular invasion |  |  | 0.972 |  |  |  | <0.001 |  |  |  | 0.008 |
| No | 117 | 118 |  |  | 92 | 55 |  |  | 128 | 107 |  |
| Yes | 46 | 46 |  |  | 72 | 108 |  |  | 35 | 57 |  |
| Perineural invasion |  |  | 0.293 |  |  |  | 0.025 |  |  |  | <0.001 |
| No | 78 | 69 |  |  | 127 | 108 |  |  | 94 | 53 |  |
| Yes | 85 | 95 |  |  | 37 | 55 |  |  | 69 | 111 |  |
| 5-Fua |  |  | 0.611 |  |  |  | 0.163 |  |  |  | 0.408 |
| Yes | 89 | 97 |  |  | 97 | 89 |  |  | 94 | 92 |  |
| No | 58 | 56 |  |  | 50 | 64 |  |  | 52 | 62 |  |

**Table-1. Association of CD66b+cells with clinicopathological feathers in Non, IM and TC of gastric cancer**

Note: a Fluoropyrimidine-based adjuvant chemotherapy, mostly including capecitabine plus platinum, capecitabine alone, or S1 (combined tegafur, gimeracil, and oteracil), in patients at advanced stage or early stage tumors with lymph node metastasis in this retrospective study.

Abbreviations: Non: Nontumoral tissues; IM: invasive margin; TC: tumor center; ASA: American Society of Anesthesiology.